BeyondSpring Inc. Profile Avatar - Palmy Investing

BeyondSpring Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has co…

Biotechnology
US, New York [HQ]
Financials

Analysts

Reported
Past Estimate Consensus
Future Estimate Consensus
BeyondSpring Inc. can't present any analysts estimates at the moment detail analysis.
End of BYSI's Analysis
CIK: 1677940 CUSIP: G10830100 ISIN: KYG108301006 LEI: - UEI: -
Secondary Listings
BYSI has no secondary listings inside our databases.